AI tools bring new hope for cardiovascular medicine
Researchers call for global collaboration to bring precision heart medicine to patients and save millions of lives.
AI, omics, and systems biology enable targeted drugs for heart disease pathways once considered untreatable. A new study in Frontiers in Science highlights how these innovations could revolutionise treatment and save millions of lives.
Heart disease remains the leading global killer, partly because generic treatments like statins do not account for individual biological differences.
Researchers say AI-powered precision medicine can identify new gene and protein targets, enabling personalised therapies for each patient’s unique heart disease.
RNA-based drugs are emerging as an up-and-coming solution. Unlike conventional medicines that reach only limited protein targets, RNA therapies can influence almost any gene and may be developed more quickly.
Early trials show they can lower cholesterol more effectively than traditional approaches, with potential to address long-standing ‘undruggable’ pathways in cardiovascular disease.
Experts say realising these treatments requires global leadership and collaboration across academia, industry, and healthcare. Bold investment and open science are crucial to make precision medicine global and reduce heart disease, expected to cause 26 million deaths annually by 2030.
Would you like to learn more about AI, tech and digital diplomacy? If so, ask our Diplo chatbot!
